Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
about
Cardiovascular effects of hormone therapy for prostate cancerStroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic reviewMen with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate CancerTestosterone and weight loss: the evidence.Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice.Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol.Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studiesThe modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Management of metastatic hormone-sensitive prostate cancer.Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review.Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.A Cost-Utility Analysis of Prostate Cancer Screening in Australia.No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong.Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study.Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.Metabolic changes in patients with prostate cancer during androgen deprivation therapy.Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.[Cardiovascular risks of androgen deprivation therapy for prostate cancer].Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
P2860
Q26801112-EBEA0525-D11D-488E-9A9E-9473A8136AD9Q28069320-C3231169-0305-4C82-9C2A-50749D08A8B0Q31111735-4C7AC575-1133-451E-8C13-D8BF2C6722E1Q33819775-5E4C92FC-E314-49B5-8E94-2F0C73CED5E6Q34134273-8202F9AD-1133-424A-86DF-AAE5795DAAD0Q35213928-8306041D-B8FD-4C20-8316-230C55F011BDQ36490409-2B5E44D8-9350-4578-990E-337CF85EC0AFQ36714085-0492775B-BCE2-459D-961F-825393EDC98FQ37063622-3CBA148B-188C-4EBB-B849-E4B3112B8BE0Q37205661-055B04E5-2B42-4E9E-B85A-D08FC0A7F065Q37708169-BD645682-A2D6-4021-BEEA-0453B6A09CC0Q38261253-04123BE6-89F5-420A-87F9-6889D1D5443DQ38353835-0A63E067-8118-47A2-9625-D3BBBEE40C1BQ38370997-760C1839-E253-482B-83F9-2B7E0AFDFCCCQ38619677-73D177E1-5D8D-4B04-8F6E-EF454054AE5FQ38671819-81D9A88B-D5EE-4C62-94F8-7870B5D8433AQ38803264-35DFC8FF-E334-4AA0-98AA-11F6238206CBQ38817011-C54F8486-1C75-479C-AC68-4134E2BEDEBFQ38852165-C7D3E9F4-4746-491E-A46D-70B3408ACE05Q39247489-7A19D032-93E2-46E9-8CC8-379ED939BDE8Q39273026-A34FB782-F900-415E-9375-B326F506CD96Q40164167-5CDF602C-E680-4915-95CF-8222B2C4752AQ40614195-BFD6FBA9-69E0-4A0B-9AB5-77416FF4B290Q40797796-9DF25FEB-C0BB-439A-A213-C92250601B3EQ41339127-47C4701C-CA2A-4272-9FD4-B76ACC683BE2Q41669642-2299A845-8348-4558-9B93-F50A51F0E3EBQ42290613-52053393-B1BE-4220-8D9F-57FF319250EBQ43242594-21BF839D-25D9-4EE0-993A-0751E67D2169Q43992393-3166B79B-543C-40F4-A73F-C467F40C2AAAQ47754588-96610EAA-CF46-434A-AA55-1D22F2E00055Q48167919-A1BF0113-87EC-490C-9A24-677EC0F0CF0AQ49204760-1E5D8F8B-6AE4-43C8-B6EB-416F592E83F8Q52854661-07E6EAB7-996B-4291-8C0F-EAFD3E108002Q57108196-D54DBB37-D78C-4263-A64E-84B23624ADB0
P2860
Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Androgen-deprivation therapy i ...... population-based cohort study.
@en
type
label
Androgen-deprivation therapy i ...... population-based cohort study.
@en
prefLabel
Androgen-deprivation therapy i ...... population-based cohort study.
@en
P1433
P1476
Androgen-deprivation therapy i ...... population-based cohort study.
@en
P2093
Christina G Jespersen
Michael Borre
P304
P356
10.1016/J.EURURO.2013.02.002
P407
P577
2013-02-12T00:00:00Z